Quest Diagnostics Incorporated (DGX) Q2 2017 Earnings Results

Quest Diagnostics Beats on EPS, Stock Down 1.15%

Quest Diagnostics reported a better-than-expected EPS, which indicates solid performance in profitability. However, the stock fell by 1.15% following the announcement, likely due to the lack of revenue figures and forward guidance. Investors may be cautious without clear indicators of future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.55	N/A	+7.77%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting efforts to enhance operational efficiencies. However, they did not provide specific guidance for the upcoming quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on improving operational efficiencies.

Quest Diagnostics Beats on EPS, Stock Down 1.15%

Key numbers

Management commentary

Quest Diagnostics Incorporated

More earnings this week

Quest Diagnostics Beats on EPS, Stock Down 1.15%

Key numbers

Management commentary